Regulatory Lilly’s new obesity pill linked to ‘serious’ safety signals, FDA requests more data BioSpaceThe FDA is asking Eli Lilly to submit cardiovascular and liver safety data from an ongoing Phase 3 trial of Foundayo by July.RegulatoryMetabolic & GLP-1Read full story pharminent April 15, 2026 BioSpace The FDA is asking Eli Lilly to submit cardiovascular and liver safety data from an ongoing Phase 3 trial of Foundayo by July. RegulatoryMetabolic & GLP-1Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Takeda continues to prune partnerships, cuts ties with mRNA-targeting Veritas In SilicoNext: Amazon launches its AI drug discovery platform Related Stories Regulatory Outlook Therapeutics Secures FDA Approval for LYTENAVA pharminent July 31, 2026 Regulatory Outlook finally claims FDA approval for AMD drug pharminent July 27, 2026 Regulatory Outlook Therapeutics wins FDA approval for Lytenava in wet AMD pharminent July 27, 2026
